Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas
Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) and has been shown to have antineoplastic activity in addition to its use as an immunosuppressive agent for the prevention of organ transplant rejection. We report the use of everolimus for the compassionate treatment of four eld...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Case Reports in Dermatological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2013/604301 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549366150201344 |
|---|---|
| author | Laura Eibenschutz Delia Colombo Caterina Catricalà |
| author_facet | Laura Eibenschutz Delia Colombo Caterina Catricalà |
| author_sort | Laura Eibenschutz |
| collection | DOAJ |
| description | Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) and has been shown to have antineoplastic activity in addition to its use as an immunosuppressive agent for the prevention of organ transplant rejection. We report the use of everolimus for the compassionate treatment of four elderly, nontransplant patients presenting with multiple basal cell carcinomas (BCC). All patients had a long history of BCC, had refused surgery as a current treatment option, and did not respond to alternative treatments (including topical 5-fluorouracil and imiquimod). Patients were treated with oral everolimus (1.5–3.0 mg daily) for 12 months or longer: a complete and sustained response was seen in one case, and partial responses were seen in two other cases. Everolimus was well tolerated in these elderly patients. These promising preliminary data suggest that further dose-finding, controlled clinical studies are warranted to evaluate the antineoplastic effects of everolimus in patients affected by BCC who cannot or will not undergo surgery. |
| format | Article |
| id | doaj-art-35ad53f993444ab6bcbe51917ad8d924 |
| institution | Kabale University |
| issn | 2090-6463 2090-6471 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Dermatological Medicine |
| spelling | doaj-art-35ad53f993444ab6bcbe51917ad8d9242025-02-03T06:11:27ZengWileyCase Reports in Dermatological Medicine2090-64632090-64712013-01-01201310.1155/2013/604301604301Everolimus for Compassionate Use in Multiple Basal Cell CarcinomasLaura Eibenschutz0Delia Colombo1Caterina Catricalà2Dipartimento Clinico Sperimentale di Dermatologia Oncologica, Istituto Santa Maria e San Gallicano IRCCS, Via Fermo Ognibene 23, 00144 Roma, ItalyNovartis Farma Italia, 20065 Origgio, Varese, ItalyDipartimento Clinico Sperimentale di Dermatologia Oncologica, Istituto Santa Maria e San Gallicano IRCCS, Via Fermo Ognibene 23, 00144 Roma, ItalyEverolimus is an inhibitor of the mammalian target of rapamycin (mTOR) and has been shown to have antineoplastic activity in addition to its use as an immunosuppressive agent for the prevention of organ transplant rejection. We report the use of everolimus for the compassionate treatment of four elderly, nontransplant patients presenting with multiple basal cell carcinomas (BCC). All patients had a long history of BCC, had refused surgery as a current treatment option, and did not respond to alternative treatments (including topical 5-fluorouracil and imiquimod). Patients were treated with oral everolimus (1.5–3.0 mg daily) for 12 months or longer: a complete and sustained response was seen in one case, and partial responses were seen in two other cases. Everolimus was well tolerated in these elderly patients. These promising preliminary data suggest that further dose-finding, controlled clinical studies are warranted to evaluate the antineoplastic effects of everolimus in patients affected by BCC who cannot or will not undergo surgery.http://dx.doi.org/10.1155/2013/604301 |
| spellingShingle | Laura Eibenschutz Delia Colombo Caterina Catricalà Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas Case Reports in Dermatological Medicine |
| title | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
| title_full | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
| title_fullStr | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
| title_full_unstemmed | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
| title_short | Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas |
| title_sort | everolimus for compassionate use in multiple basal cell carcinomas |
| url | http://dx.doi.org/10.1155/2013/604301 |
| work_keys_str_mv | AT lauraeibenschutz everolimusforcompassionateuseinmultiplebasalcellcarcinomas AT deliacolombo everolimusforcompassionateuseinmultiplebasalcellcarcinomas AT caterinacatricala everolimusforcompassionateuseinmultiplebasalcellcarcinomas |